Stock listing
Frankfurt:CUP0 Chugai Pharmaceutical Co., Ltd. Aktie
German listing (Frankfurt) of Chugai Pharmaceutical Co., Ltd. · home listing Tokyo:4519
Follow Chugai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · FWB:CUP0
€19.50 EUR -0.40 (-2.0%)
Close on Nov 19, 2026
- Day range
- €19.50 – €19.50 EURNov 19, 2026
- Market cap
- €64.18B EURAt the close on Nov 19, 2026 · price × 3.29B shares outstanding
- 52-week range
- €16.15 – €28.64 EURLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 58 days with no trades · last 3 months, Aug 19, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:CHGCY | $22.26 USD | -0.20 (-0.9%) | 218,409 | $22.81 | $22.81 | $22.01 | $22.46 | Close on Nov 20, 2026 |
| OTC:CHGCF | $44.81 USD | +0.488 (+1.1%) | 561 | $44.81 | $44.81 | $44.81 | $44.32 | Close on Nov 20, 2026 |
| Frankfurt:CUP | €40.51 EUR | -0.67 (-1.6%) | — | €40.54 | €40.65 | €40.51 | €41.18 | Close on Nov 20, 2026 |
| Munich:CUP | €40.08 EUR | -1.67 (-4.0%) | — | €40.64 | €40.64 | €40.08 | €41.75 | Close on Nov 20, 2026 |
| Dusseldorf:CUP | €39.61 EUR | -1.17 (-2.9%) | — | €40.09 | €40.58 | €39.61 | €40.78 | Close on Nov 20, 2026 |
| Frankfurt:CUP0 | €19.50 EUR | -0.40 (-2.0%) | — | €19.50 | €19.50 | €19.50 | €19.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 6, 2026 · FWB:CUP0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €18.86 | +0.259 | +1.4% | €18.86 | €18.86 | €18.86 | 0 | |
| €18.61 | +0.46 | +2.5% | €18.61 | €18.61 | €18.61 | 0 | |
| €18.15 | -0.16 | -0.9% | €18.15 | €18.15 | €18.15 | 0 | |
| €18.31 | -0.173 | -0.9% | €18.31 | €18.31 | €18.31 | 0 | |
| €18.48 | +0.732 | +4.1% | €18.48 | €18.48 | €18.48 | 0 | |
| €17.75 | -0.241 | -1.3% | €17.75 | €17.75 | €17.75 | 0 | |
| €17.99 | -0.901 | -4.8% | €17.99 | €17.99 | €17.99 | 0 | |
| €18.89 | +0.421 | +2.3% | €18.89 | €18.89 | €18.89 | 0 | |
| €18.47 | +0.152 | +0.8% | €18.47 | €18.47 | €18.47 | 0 | |
| €18.32 | -0.567 | -3.0% | €18.32 | €18.32 | €18.32 | 0 | |
| €18.88 | +1.795 | +10.5% | €18.88 | €18.88 | €18.88 | 0 | |
| €17.09 | -0.275 | -1.6% | €17.09 | €17.09 | €17.09 | 0 | |
| €17.36 | +0.512 | +3.0% | €17.36 | €17.36 | €17.36 | 0 | |
| €16.85 | -0.089 | -0.5% | €16.85 | €16.85 | €16.85 | 0 | |
| €16.94 | -0.695 | -3.9% | €16.94 | €16.94 | €16.94 | 0 | |
| €17.63 | +1.447 | +8.9% | €17.63 | €17.63 | €17.63 | 0 | |
| €16.19 | -0.14 | -0.9% | €16.19 | €16.19 | €16.19 | 0 | |
| €16.33 | +0.10 | +0.6% | €16.33 | €16.33 | €16.33 | 0 | |
| €16.23 | -0.092 | -0.6% | €16.23 | €16.23 | €16.23 | 0 | |
| €16.32 | +0.172 | +1.1% | €16.32 | €16.32 | €16.32 | 0 | |
| €16.15 | -0.226 | -1.4% | €16.15 | €16.15 | €16.15 | 0 | |
| €16.37 | +0.175 | +1.1% | €16.37 | €16.37 | €16.37 | 0 | |
| €16.20 | -0.262 | -1.6% | €16.20 | €16.20 | €16.20 | 0 | |
| €16.46 | +0.129 | +0.8% | €16.46 | €16.46 | €16.46 | 0 | |
| €16.33 | 0.00 | 0.0% | €16.33 | €16.33 | €16.33 | 0 | |
| €16.33 | -0.168 | -1.0% | €16.33 | €16.33 | €16.33 | 0 | |
| €16.50 | +0.28 | +1.7% | €16.50 | €16.50 | €16.50 | 0 | |
| €16.22 | -0.489 | -2.9% | €16.22 | €16.22 | €16.22 | 0 | |
| €16.71 | -0.641 | -3.7% | €16.71 | €16.71 | €16.71 | 0 | |
| €17.35 | -0.128 | -0.7% | €17.35 | €17.35 | €17.35 | 0 | |
| €17.48 | -0.295 | -1.7% | €17.48 | €17.48 | €17.48 | 0 | |
| €17.77 | -0.227 | -1.3% | €17.77 | €17.77 | €17.77 | 0 | |
| €18.00 | +0.112 | +0.6% | €18.00 | €18.00 | €18.00 | 0 | |
| €17.89 | -0.084 | -0.5% | €17.89 | €17.89 | €17.89 | 0 | |
| €17.97 | +0.376 | +2.1% | €17.97 | €17.97 | €17.97 | 0 | |
| €17.60 | +0.497 | +2.9% | €17.60 | €17.60 | €17.60 | 0 | |
| €17.10 | +0.03 | +0.2% | €17.10 | €17.10 | €17.10 | 0 | |
| €17.07 | +0.025 | +0.1% | €17.07 | €17.07 | €17.07 | 0 | |
| €17.04 | -0.009 | -0.1% | €17.04 | €17.04 | €17.04 | 0 | |
| €17.05 | +0.20 | +1.2% | €17.05 | €17.05 | €17.05 | 0 | |
| €16.85 | -0.219 | -1.3% | €16.85 | €16.85 | €16.85 | 0 | |
| €17.07 | -0.021 | -0.1% | €17.07 | €17.07 | €17.07 | 0 | |
| €17.09 | -0.538 | -3.1% | €17.09 | €17.09 | €17.09 | 0 | |
| €17.63 | -0.006 | 0.0% | €17.63 | €17.63 | €17.63 | 0 | |
| €17.64 | -0.37 | -2.1% | €17.64 | €17.64 | €17.64 | 0 | |
| €18.01 | +0.297 | +1.7% | €18.01 | €18.01 | €18.01 | 0 | |
| €17.71 | +0.248 | +1.4% | €17.71 | €17.71 | €17.71 | 0 | |
| €17.46 | -0.094 | -0.5% | €17.46 | €17.46 | €17.46 | 0 | |
| €17.56 | -0.126 | -0.7% | €17.56 | €17.56 | €17.56 | 0 | |
| €17.68 | +0.106 | +0.6% | €17.68 | €17.68 | €17.68 | 0 | |
| €17.58 | -0.241 | -1.4% | €17.58 | €17.58 | €17.58 | 0 | |
| €17.82 | +0.025 | +0.1% | €17.82 | €17.82 | €17.82 | 0 | |
| €17.79 | -0.027 | -0.2% | €17.79 | €17.79 | €17.79 | 0 | |
| €17.82 | -0.114 | -0.6% | €17.82 | €17.82 | €17.82 | 0 | |
| €17.93 | +0.08 | +0.4% | €17.93 | €17.93 | €17.93 | 0 | |
| €17.85 | -0.246 | -1.4% | €17.85 | €17.85 | €17.85 | 0 | |
| €18.10 | +0.566 | +3.2% | €18.10 | €18.10 | €18.10 | 0 | |
| €17.53 | +0.044 | +0.3% | €17.53 | €17.53 | €17.53 | 0 |
- Ticker
- Frankfurt:CUP0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 27, 2026
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Latest earnings call · Jul 24, 2026
Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 27, 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Oct 27, 2026
Closed €18.47 (+0.8%) on Oct 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)
Oct 27, 2026
Closed €18.47 (+0.8%) on Oct 27, 2026
F. Hoffmann-La Roche Announces Third Quarter Sales 2026
Oct 22, 2026
Closed €17.09 (-1.6%) on Oct 22, 2026
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Sep 28, 2026
Closed €17.35 (-0.7%) on Sep 28, 2026
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Sep 9, 2026
Closed €17.09 (-3.1%) on Sep 9, 2026
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
Aug 18, 2026
Closed €17.49 (-1.9%) on Aug 18, 2026
Chugai Announces 2026 2nd Quarter Results
Jul 27, 2026
Closed €18.28 (-0.7%) on Jul 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
Jul 24, 2026
Closed €18.41 (+0.3%) on Jul 24, 2026
F. Hoffmann-La Roche Announces Half Year Results 2026
Jul 23, 2026
Closed €18.36 (-3.2%) on Jul 23, 2026
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
Jun 22, 2026
Closed €19.28 (-0.8%) on Jun 22, 2026
Chugai Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 31 in all · newest Oct 27, 2026 · oldest 2025
- Calls
- 9 calls with a replay · 9 with a transcript · latest Jul 24, 2026
- Decks
- 107 decks · latest Oct 27, 2026
Where Chugai Pharmaceutical Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Tokyo:4519 中外製薬 · Home listing | Tokyo | Japan | JPY |
| OTC:CHGCY | OTC | United States | USD |
| OTC:CHGCF | OTC | United States | USD |
| gettex:CUP | gettex | Germany | EUR |
| Frankfurt:CUP | Frankfurt | Germany | EUR |
| Tradegate:CUP | Tradegate | Germany | EUR |
| LS Exchange:857216 | LS Exchange | Germany | EUR |
| Lang & Schwarz:857216 | Lang & Schwarz | Germany | EUR |
| BMV:4519N | BMV | Mexico | MXN |
| Munich:CUP | Munich | Germany | EUR |
| Stuttgart:CUP | Stuttgart | Germany | EUR |
| Hamburg:CUP | Hamburg | Germany | EUR |
| Dusseldorf:CUP | Dusseldorf | Germany | EUR |
| gettex:CUP0 | gettex | Germany | EUR |
| Hanover:CUP | Hanover | Germany | EUR |
| BIVA:4519N | BIVA | Mexico | MXN |
| Frankfurt:CUP0 · This page | Frankfurt | Germany | EUR |
| Munich:CUP0 | Munich | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Osamu Okuda | Representative Director, President & CEO |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Hitoshi Iikura | Director, Executive Vice President |
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
Board
| Director | Role |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
| Hitoshi Iikura | Director, Executive Vice President |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) |
| Osamu Okuda | Representative Director, President & CEO |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) |
| Teresa A. Graham | Director |
| Thomas Schinecker | Director |
Events
| Call | When | Status |
|---|---|---|
| Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call | Fri, Jul 24, 2026 · 3:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2026 Earnings Call | Fri, Apr 24, 2026 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2025 Earnings Call | Thu, Jan 29, 2026 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2025 Earnings Call | Sat, Oct 25, 2025 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2025 Earnings Call | Thu, Jul 24, 2025 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2024 Earnings Call | Thu, Jan 30, 2025 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2024 Earnings Call | Fri, Oct 25, 2024 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2024 Earnings Call | Wed, Jul 24, 2024 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2024 Earnings Call | Wed, Apr 24, 2024 · 5:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Technical Presentation (June 2026) | Technical | 45 slides | Jun 17, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | Apr 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 53 slides | Jan 29, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 47 slides | Jul 24, 2025 |
| souzoulabo slide | 6 slides | February 2025 | |
| FY2024 Earnings Presentation | Earnings | 56 slides | Jan 30, 2025 |
Show 50 decks
This page holds 50 of 107 decks. Open Decks
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Third Quarter Sales 2026 | Oct 22, 2026 | Other filings | Tokyo Stock Exchange |
| Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA | Sep 28, 2026 | Other filings | Tokyo Stock Exchange |
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026) | Jul 24, 2026 | Interim report | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Half Year Results 2026 | Jul 23, 2026 | Interim report | Tokyo Stock Exchange |
Cap table
Built by 6ix from Chugai Pharmaceutical Co., Ltd.’s releases
- Common shares
- 1,679,057,667
- Fully diluted
- 1,679,057,667
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,679,057,667 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,679,057,667 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche · Since at least Mar 27, 2026 |
| Hitoshi Iikura | Director, Executive Vice President · Since at least Mar 27, 2026 |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO · Since at least Mar 27, 2026 |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Osamu Okuda | Representative Director, President & CEO · Since at least Sep 9, 2026 |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Teresa A. Graham | Director · Since at least Mar 27, 2026 |
| Thomas Schinecker | Director · Since at least Mar 27, 2026 |
Log in to ask 6ix AI your own questions about Chugai Pharmaceutical Co., Ltd.